Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.

Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP, Ahlquist P.

Cancer Res. 2007 May 15;67(10):4605-19.

2.

Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.

Lace MJ, Anson JR, Klussmann JP, Wang DH, Smith EM, Haugen TH, Turek LP.

J Virol. 2011 Feb;85(4):1645-54. doi: 10.1128/JVI.02093-10. Epub 2010 Dec 1.

3.

Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers.

Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS, Chae YK, Lyford-Pike S, Westra WH, Saunders JR, Sidransky D, Pai SI.

Cancer Prev Res (Phila). 2011 Feb;4(2):207-17. doi: 10.1158/1940-6207.CAPR-10-0147.

4.

E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression.

Wu L, Goodwin EC, Naeger LK, Vigo E, Galaktionov K, Helin K, DiMaio D.

Mol Cell Biol. 2000 Oct;20(19):7059-67.

5.

Modulation of therapeutic sensitivity by human papillomavirus.

Swick AD, Chatterjee A, De Costa AM, Kimple RJ.

Radiother Oncol. 2015 Sep;116(3):342-5. doi: 10.1016/j.radonc.2015.09.002. Epub 2015 Sep 10. Review.

6.

Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells.

Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA.

Oncogene. 2008 Apr 17;27(18):2575-82. Epub 2007 Nov 12.

7.

Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers.

Deng Z, Uehara T, Maeda H, Hasegawa M, Matayoshi S, Kiyuna A, Agena S, Pan X, Zhang C, Yamashita Y, Xie M, Suzuki M.

PLoS One. 2014 Nov 18;9(11):e113702. doi: 10.1371/journal.pone.0113702. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118439.

8.

Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells.

Wells SI, Aronow BJ, Wise TM, Williams SS, Couget JA, Howley PM.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7093-8. Epub 2003 May 19.

9.

Physical status and expression of HPV genes in cervical cancers.

Park JS, Hwang ES, Park SN, Ahn HK, Um SJ, Kim CJ, Kim SJ, Namkoong SE.

Gynecol Oncol. 1997 Apr;65(1):121-9.

PMID:
9103401
10.

Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.

Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH.

J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006.

PMID:
15240783
12.

Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma.

Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP.

Cancer. 1998 Dec 1;83(11):2346-52.

PMID:
9840534
13.

Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.

Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X, Luo A, Zhou J, Xu G, Meng L, Lu Y, Ma D.

Gynecol Oncol. 2007 Aug;106(2):299-304. Epub 2007 Jun 21.

PMID:
17586029
14.

DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri.

Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M.

Clin Cancer Res. 2004 May 1;10(9):3059-63.

15.

Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method.

Bishop JA, Ma XJ, Wang H, Luo Y, Illei PB, Begum S, Taube JM, Koch WM, Westra WH.

Am J Surg Pathol. 2012 Dec;36(12):1874-82. doi: 10.1097/PAS.0b013e318265fb2b.

16.

Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.

Kennedy EM, Kornepati AV, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, Kastan MB, Cullen BR.

J Virol. 2014 Oct;88(20):11965-72. doi: 10.1128/JVI.01879-14. Epub 2014 Aug 6.

17.

Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma.

Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Crémoux P, de La Rochefordière A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany E, Sastre-Garau X.

Oncogene. 2005 Oct 27;24(47):7094-104.

PMID:
16007141
18.

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08. Epub 2009 Apr 22.

19.

Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia.

Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Chandy G.

Mol Diagn. 2004;8(1):57-64.

PMID:
15230643

Supplemental Content

Support Center